Catalent Inc (NASDAQ:CTLT)‘s stock had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies in a report issued on Tuesday. They currently have a $45.00 target price on the stock. Piper Jaffray Companies’ price target points to a potential upside of 11.75% from the stock’s current price.

Several other equities analysts have also commented on CTLT. William Blair raised Catalent from a “market perform” rating to an “outperform” rating in a report on Friday, May 5th. Zacks Investment Research lowered Catalent from a “buy” rating to a “sell” rating in a report on Tuesday, May 9th. Bank of America Corporation reissued a “buy” rating and issued a $37.00 target price (up previously from $32.00) on shares of Catalent in a report on Wednesday, May 17th. Finally, BidaskClub lowered Catalent from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 27th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Catalent presently has an average rating of “Buy” and an average target price of $35.88.

Shares of Catalent (NASDAQ:CTLT) traded down 1.651% during midday trading on Tuesday, reaching $39.605. The company had a trading volume of 1,901,313 shares. The stock has a market capitalization of $4.95 billion and a price-to-earnings ratio of 45.523. Catalent has a 1-year low of $21.83 and a 1-year high of $40.44. The firm’s 50 day moving average price is $35.14 and its 200-day moving average price is $32.37.

Catalent (NASDAQ:CTLT) last posted its earnings results on Monday, August 28th. The company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.57 by $0.08. The firm had revenue of $616.90 million for the quarter, compared to analyst estimates of $547.48 million. Catalent had a return on equity of 16.95% and a net margin of 4.88%. Catalent’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.52 earnings per share. Equities research analysts expect that Catalent will post $1.60 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/piper-jaffray-companies-reiterates-overweight-rating-for-catalent-inc-ctlt/1529243.html.

In other Catalent news, SVP Christine Dolan sold 745 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $34.85, for a total transaction of $25,963.25. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Several institutional investors have recently modified their holdings of the company. BlackRock Inc. raised its position in shares of Catalent by 15.2% in the second quarter. BlackRock Inc. now owns 17,512,661 shares of the company’s stock valued at $614,695,000 after buying an additional 2,316,849 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Catalent by 3.8% in the second quarter. Vanguard Group Inc. now owns 10,119,431 shares of the company’s stock valued at $355,192,000 after buying an additional 369,526 shares during the last quarter. Janus Henderson Group PLC purchased a new position in shares of Catalent during the second quarter valued at about $239,629,000. Schroder Investment Management Group raised its position in shares of Catalent by 8.4% in the first quarter. Schroder Investment Management Group now owns 5,143,664 shares of the company’s stock valued at $146,646,000 after buying an additional 400,219 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Catalent by 4.6% in the second quarter. JPMorgan Chase & Co. now owns 5,139,690 shares of the company’s stock valued at $180,403,000 after buying an additional 226,705 shares during the last quarter.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Analyst Recommendations for Catalent (NASDAQ:CTLT)

Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.